Clinical trials: Essential Blepharospasm, open to volunteers
Blepharospasm of Both Eyelids, Blepharospasm of Left Eyelid
DaxibotulinumtoxinA for Blepharospasm
This study aims to provide real-world information about the duration, safety, and overall benefit of DaxibotulinumtoxinA (also called DAXI) treatment for adults living with blepharospasm (BSP), a condition that causes…
- Conditions
- Blepharospasm of Both Eyelids, Blepharospasm of Left Eyelid, Blepharospasm of Right Eyelid, Blepharospasm, Benign Essential
- Trial name
- BLEXI (NCT07489430)
- Testing
- Botulinum Neurotoxin Type A
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Pennsylvania
Benign Essential Blepharospasm, Hemifacial Spasm
Effects of DaxibotulinumtoxinA for Blepharospasm and Hemifacial Spasm
The goal of this clinical trial is to test the effects of DaxibotulinumtoxinA-Lanm (Daxxify) in patients with benign essential blepharospasms (BEB) and hemifacial spasms (HFS). The main questions to answer: 1.
- Trial name
- NCT06195241
- Testing
- DaxibotulinumtoxinA
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Montefiore Medical Center